What is Curis's market cap?

Curis (CRIS) has a market capitalization of $9.7M and trades on NASDAQ.

Who are Curis's competitors?

Curis's key competitors include Rigel Pharmaceuticals, Inc., AstraZeneca PLC, AbbVie Inc., and others. These companies compete in similar markets and product categories.

Who does Curis partner with?

Curis's notable partners include Aurigene Discovery Technologies Limited, Genentech, Inc., Oberland Capital Management, LLC, and others.

Where is Curis headquartered?

Curis is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2000.

Curis

CRIS

Curis Inc is a clinical-stage biotechnology company dedicated to developing small molecule drug candidates for the treatment of human cancers.

Market cap

$9.67M-58.3%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$1.25Miss by $0.96

Read the full report

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$1.0M

EPS estimate-$8.25

Competitors

By market cap

Eli Lilly$1.09T+56.4%

Johnson & Johnson$623.71B+66.9%

AbbVie$441.54B+33.2%

Gilead Sciences$167.41B+20.4%

Nurix Therapeutics, Inc.$2.6B+171%

Rigel Pharmaceuticals$809.7M+140%

ALX Oncology Holdings Inc.$277.2M+1,068%

Curis$9.7M-46.9%

By revenue growth

Rigel Pharmaceuticals+47.6%

Eli Lilly+47.4%

AbbVie+9.5%

Johnson & Johnson+7.9%

Gilead Sciences+3.5%

Nurix Therapeutics, Inc.-58.4%

By net margin

Rigel Pharmaceuticals121.51%+103pp

Eli Lilly34.99%+12.3pp

Gilead Sciences30.99%+10.2pp

Johnson & Johnson21.83%-2.6pp

AbbVie5.79%-1.5pp

Nurix Therapeutics, Inc.-928.44%-694pp

Profile

Curis Inc is a clinical-stage biotechnology company dedicated to developing small molecule drug candidates for the treatment of human cancers. The company's primary focus is on precision oncology and immuno-oncology, specifically targeting signaling pathways that drive cancer cell proliferation and survival. Its lead development candidate is emavusertib, an oral inhibitor designed to address hematologic malignancies with high unmet medical needs.

Competitive position

Curis is a clinical-stage developer focusing on niche hematologic malignancies like PCNSL and AML, utilizing an oral small molecule approach to target IRAK4 and FLT3 pathways.

GeographiesUnited States, European Union, Japan

Customer segmentsPharmaceutical companies, Healthcare providers

Business modelResearch and Development, Licensing and Royalties

SuppliersContract Research Organizations (CROs), Third-party manufacturers (CMOs), Raw material suppliers, Academic and research institution collaborators

CustomersStrategic licensing partners, Clinical trial sites, Hospitals and oncology centers

CountryUnited States of America

Listed2000

Employees49.0

CEOJames Dentzer

SectorHealthcare

IndustryBiotechnology

Websitecuris.com

FilingsSEC EDGAR

Questions, answered.

What is Curis's market cap?: Curis (CRIS) has a market capitalization of $9.7M and trades on NASDAQ.
Who are Curis's competitors?: Curis's key competitors include Rigel Pharmaceuticals, Inc., AstraZeneca PLC, AbbVie Inc., and others. These companies compete in similar markets and product categories.
Who does Curis partner with?: Curis's notable partners include Aurigene Discovery Technologies Limited, Genentech, Inc., Oberland Capital Management, LLC, and others.
Where is Curis headquartered?: Curis is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2000.